RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Rocket Pharmaceuticals (RCKT) incurred a loss of 56 cents per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 59 cents. The company reported a loss of 66 cents per share in the year-ago quarter.In the absence of a marketed product in its portfolio, Rocket Pharmaceuticals did not record any revenues in the reported quarter. The Zacks Consensus Estimate for the company’s total revenues was $8 million. (See the Zacks Earnings Calendar to stay ahead of market-making n ...